{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-26-012879","form_type":"8-K","ticker":"GNPX","cik":"0001595248","company_name":"Genprex, Inc.","filed_at":"2026-04-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.542130+00:00","generated_at":"2026-05-15T05:06:41.769203+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses","bullets":["New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.","Acclaim-1 Phase 2a enrolling; Phase 1 showed no DLTs, one patient had partial remission for ~42 months (60 courses) on Reqorsa+Tagrisso.","Acclaim-3 Phase 2 enrolling; Phase 1 showed no DLTs, one patient had unconfirmed partial remission after 24 cycles (>18 months) on Reqorsa+Tecentriq.","Both trials combine Reqorsa (quaratusugene ozeplasmid) with approved targeted therapies; early signs of efficacy reported."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-012879","json":"https://secwatch.observer/filing/0001437749-26-012879.json","markdown":"https://secwatch.observer/filing/0001437749-26-012879.md","text":"https://secwatch.observer/filing/0001437749-26-012879.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/0001437749-26-012879-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595248/000143774926012879/gnpx20260329_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:06:41.769203+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}